1. Scrip
  2. >>Focus On Asia
  3. >>China

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

From HARMONi-2 Vs Keytruda In NSCLC

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Investors' expectations are high that Akeso and Summit Therapeutics' ivonescimab could eventually best Merck's Keytruda in overall survival for the first-line treatment of PD-L1-positive non-small cell lung cancer. (Shutterstock)

Akeso apparently disagreed with investors’ reactions after the Chinese biotech on 25 April provided an early release of preliminary overall survival (OS) data from an interim analysis of a high-stakes head-to-head Phase III trial of ivonescimab versus Keytruda (pembrolizumab) in non-small cell lung cancer (NSCLC).

Key Takeaways
  • Akeso/Summit's ivonescimab has shown a preliminary overall survival hazard ratio of 0.777 in the head-to-head HARMONi-2 study versus Keytruda in NSCLC, with no p value disclosed.

While ivonescimab, Akeso’s bispecific anti-PD-1/VEGF antibody, clearly beat Merck & Co.’s PD-1-targeting blockbuster in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Clinical Trials

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.